Journal of Cardiac Failure
Volume 13, Issue 8 , Pages 609-617 , October 2007

The Effect of KW-3902, an Adenosine A1 Receptor Antagonist, on Renal Function and Renal Plasma Flow in Ambulatory Patients With Heart Failure and Renal Impairment

  • Howard C. Dittrich, MD

      Affiliations

    • NovaCardia, Inc, San Diego, California
    • Corresponding Author InformationReprint requests: Howard C. Dittrich, MD, NovaCardia, Inc., 12750 High Bluff Drive, Suite 300, San Diego, CA 92130.
    • ,
  • Dinesh K. Gupta, MD

      Affiliations

    • Cardiology Group PC, Tullahoma, Tennessee
    • ,
  • Terrence C. Hack, MD

      Affiliations

    • Primary Care Cardiology Research, Ayer, Massachusetts
    • ,
  • Thomas Dowling, PhD

      Affiliations

    • University of Maryland, Baltimore, Maryland
    • ,
  • Janice Callahan, PhD

      Affiliations

    • Callahan Associates Inc., San Diego, California
    • ,
  • Scott Thomson, MD

      Affiliations

    • Nephrology-Hypertension Division, University of California San Diego and Veterans Affairs San Diego Healthcare System, San Diego, California

Received 11 March 2007 ,Revised 15 August 2007 ,Accepted 17 August 2007.

References 

  1. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a perspective cohort study. Circulation. 2004;109:1004–1009
  2. Vallon V, Muhlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev. 2006;86:901–940
  3. Churchill PC, Bidani AK. Adenosine and renal function. In:  Williams M editors. Adenosine and adenosine receptors. Totowa, NJ: HUYmana; 1990;Chapter 9
  4. Takeda M, Yoshitomi K, Imai M. Regulation of Na(+)–3HCO3– cotransport in rabbit proximal convoluted tubule via adenosine A1 receptor. Am J Physiol. 1993;265:F511–F519
  5. Weihprecht H, Lorenz JN, Briggs JP, Schnermann J. Synergistic effects of angiotensin and adenosine in the renal microvasculature. Am J Physiol. 1994;266:F227–F239
  6. Thomson S, Bao D, Deng A, Vallon V. Adenosine formed by 5'-nucleotidase mediates tubuloglomerular feedback. J Clin Invest. 2000;106:289–298
  7. Wilcox CS, Welch WJ, Schreiner GF, Belardinelli L. Natriuretic and diuretic actions of a highly selective adenosine A1 receptor antagonist. J Am Soc Nephrol. 1999;10:714–720
  8. Friedberg CK, Taymor R, Minor JB, Halpern M. The use of Diamox, a carbonic anhydrase inhibitor, as an oral diuretic in patients with congestive heart failure. N Engl J Med. 1953;248:883–889
  9. Tucker BJ, Steiner RW, Gushwa LC, Blantz RC. Studies on the tubulo-glomerular feedback system in the rat. The mechanism of reduction in filtration rate with benzolamide. J Clin Invest. 1978;62:993–1004
  10. Cockcroft D, Gault MD. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
  11. Dowling TC, Frye RF, Zemaitis MA. Simultaneous determination of p-aminohippuric acid, acetyl-p-aminohippuric acid and iothalamate in human plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1998;716:305–313
  12. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348–1353
  13. Blantz RC, Konnen KS, Tucker BJ. Angiotensin II effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat. J Clin Invest. 1976;57:419–434
  14. Dworkin LD, Ichikawa I, Brenner BM. Hormonal modulation of glomerular function. Am J Physiol. 1983;244:F95–F104
  15. Guyton AC. Long-term arterial pressure control: an analysis from animal experiments and computer and graphic models. Am J Physiol. 1990;259(5 Pt 2):R865–R877Review
  16. Givertz, MM, Massie BM, Fields TK, Pearson LL, Dittrich HC, the CKI-201 and CKI-202 Investigators. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol (in press).

 This study was sponsored by NovaCardia, Inc. (San Diego, California) and was conducted under an Investigational New Drug Application with the US Food and Drug Administration. All costs of this study were borne by NovaCardia, Inc.Howard Dittrich is an employee of NovaCardia, Inc., Dinesh Gupta and Terrence Hack received grants from NovaCardia, Inc. Thomas Dowling, Janice Callahan, and Scott Thomson received consulting fees from NovaCardia, Inc.Clinical Trial Registration information: (http://www.clinicaltrials.gov) NCT00159614.

PII: S1071-9164(07)01040-8

doi: 10.1016/j.cardfail.2007.08.006

Journal of Cardiac Failure
Volume 13, Issue 8 , Pages 609-617 , October 2007

Article Tools

* Image Usage & Resolution